PVX-001: open-source Covid-19 vaccine starts Phase 1 trial

PopVax, a non-profit organization, has initiated the Phase 1 clinical trial of its open-source Covid-19 vaccine candidate, PVX-001. The trial is being conducted in collaboration with the University of the West Indies and the University of Oxford. The vaccine is designed to provide long-term immunity against Covid-19 and is being developed in collaboration with the tech community. The trial will involve 50 participants, with the goal of assessing the vaccine's safety and efficacy. PopVax aims to make the vaccine available at an affordable price and has released its design specifications, allowing others to contribute to its development. The trial is being conducted in Jamaica, where the University of the West Indies is located.